AbbVie Inc.

AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (Venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course
Health, Medical, & Dental Supplies and Equipment

AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (Venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course

- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1] - Of the 130 patients who completed rituximab plus the 24-month fixed duration of venetoclax and remained off therapy for a median of 9.9 months, the...

Read More »
Packaging Products & Equipment

AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data

- Upadacitinib monotherapy showed improvements in physical function, a measure that assesses patients' ability to perform daily activities and level of disability, versus methotrexate at week 14 - Upadacitinib-treated patients reported significantly greater improvements in health-related quality of life, reductions in pain and the duration and severity of morning joint stiffness compared to...

Read More »
Health, Medical, & Dental Supplies and Equipment

AbbVie Receives Health Canada Approval of ORILISSA™ (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis

Endometriosis affects up to one in 10 women of reproductive age in Canada. 7 out of 10 women being managed for endometriosis have unresolved pain throughout the month. The approval of ORILISSA is supported by data from two replicate Phase 3 studies, which evaluated nearly 1,700 women. In clinical trials, ORILISSA™demonstrated sustained relief over 12 months across the two most common types...

Read More »
Mergers & Acquisitions

AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep

Agreements Contingent on FTC and European Commission Approval and Completion of AbbVie's Pending Acquisition of Allergan North Chicago, Ill. and Dublin, Jan. 27, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan (NYSE: AGN), a leading global pharmaceutical company, today announced that Allergan has entered into definitive agreements...

Read More »
Company News

AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at The 28th European Academy of Dermatology and Venereology (EADV) Congress

Twenty new abstracts underscore AbbVie's commitment to advancing standards of care for people living with serious skin diseases North Chicago, Ill., Oct. 9, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that it will present new results evaluating the safety and efficacy of SKYRIZI™ (risankizumab) at 2.5 years in adult patients...

Read More »
Company News

AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction

NORTH CHICAGO, Ill., Sept. 27, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that, as expected, AbbVie and Allergan (NYSE: AGN) have each received a Request for Additional Information (Second Request) from the Federal Trade Commission (FTC) in connection with AbbVie's pending acquisition of Allergan. The Second Request was...

Read More »
Company News

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

North Chicago, Ill. and Menlo Park, Calif., Feb. 11, 2019/PRNewswire/ -- AbbVie (NYSE: ABBV),  Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma. B-cell maturation antigen (BCMA) has emerged as an...

Read More »
AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (Venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course
Health, Medical, & Dental Supplies and Equipment

AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (Venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course

- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1] - Of the 130 patients who completed rituximab plus the 24-month fixed duration of venetoclax and remained off therapy for a median of 9.9 months, the...

Read More »
Packaging Products & Equipment

AbbVie's Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data

- Upadacitinib monotherapy showed improvements in physical function, a measure that assesses patients' ability to perform daily activities and level of disability, versus methotrexate at week 14 - Upadacitinib-treated patients reported significantly greater improvements in health-related quality of life, reductions in pain and the duration and severity of morning joint stiffness compared to...

Read More »
Company News

AbbVie Announces Global Resolution of HUMIRA® (Adalimumab) Patent Disputes with Fresenius Kabi

- Agreements Provide Non-Exclusive License to Fresenius Kabi for HUMIRA-Related Intellectual Property in the U.S. Effective September 30, 2023, and in Other Markets on Different Dates - Fresenius Kabi Acknowledges Validity of AbbVie's Intellectual Property for HUMIRA NORTH CHICAGO, Ill., Oct. 18, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today global resolution of all intellectual...

Read More »
Health, Medical, & Dental Supplies and Equipment

AbbVie Receives Health Canada Approval of ORILISSA™ (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis

Endometriosis affects up to one in 10 women of reproductive age in Canada. 7 out of 10 women being managed for endometriosis have unresolved pain throughout the month. The approval of ORILISSA is supported by data from two replicate Phase 3 studies, which evaluated nearly 1,700 women. In clinical trials, ORILISSA™demonstrated sustained relief over 12 months across the two most common types...

Read More »

All Topics

COVID-19 Response Suppliers COVID-19 Response:
Can Your Company Help Provide Critical Supplies?

We are using the power of our platform to aid in the mass shortage of critical supplies. If your company can help provide supplies, capabilities, or materials for products such as N-95 Masks and Tyvek SuitsPlease let us know.

COVID-19 Response Suppliers